Title: Our strengths:
1(No Transcript)
2We rapidly deliver break-through products in
targeted fast growing civilian and military
health care markets where we can leverage our
leap-ahead core technologies.
- Our strengths
- Leading edge talent
- Preeminent management team
- Efficient corporate form
- Advanced core technologies
- Full product pipeline
The Bio-Tech Company for the New Millennium
3Company
- Founded in April 1997, Quick-Med Technologies is
a bio-medical device company developing its
proprietary, broad-based technologies for
consumer healthcare markets and advanced military
medical use. - QMTs two core technologies under development
are - Ilomastat, and
- NIMBUS
The Bio-Tech Company for the New Millennium
4Scientific Team
- Christopher D. Batich, Ph.D. Expert in
Bio-Medical Engineering and Material Science - Gerald M. Olderman, Ph.D. Expert in Physical
and Surface Chemistry - Gregory Schultz, Ph.D. Expert in Wound
Healing and Skin Chemistry - William Toreki, Ph.D. Expert in Polymer
Chemistry -
The Bio-Tech Company for the New Millennium
5University of Florida at Gainesville
- Quick-Med Technologies has exclusive licenses
from the University of Florida at Gainesville for
the NIMBUS Ilomastat technologies.
The University of Florida is excited about its
new partnership with Quick-Med, it is an
excellent example of the proactive flexible
approach OTL has taken to assist promising new
companies developing UF technologies, which are
the basis for new products and enhancements to
existing product lines. We are hopeful that
through the efforts of our office and our new
partnership with Quick-Med, these technologies
will soon be applied to improving the human
condition. David Day, Director of the Office of
Technology Licensing (OTL) at the University of
Florida
The Bio-Tech Company for the New Millennium
6Core Technology NIMBUS
- Novel Intrinsically MicroBiocidal Utility
Substrate (NIMBUS ) - A family of advanced non-toxic polymers
engineered to have antimicrobial, super
absorbent, hemostatic and other properties with
significant applications in the following
markets - Institutional
- Consumer
- Industrial
The Bio-Tech Company for the New Millennium
7Features of the NIMBUS Substrate
- A non-extractable active agent is permanently
attached to natural fibers. - The microbicide has a very broad spectrum of
activity. - Bacterial resistance does not affect NIMBUS as
it does with antibiotics because Nimbus works by
the process of cell disruption. - Efficacy is not lost in the presence of proteins
from food or body liquids. - High surface charge density enables the high
performance. - NIMBUS exhibits a rapid action against
bacteria, viruses and fungi. - Effective over a prolonged interval of at least
seven days. - Flexible design allows the addition of dyes or
other active agents. - A superabsorbent form is available as well.
- The treatment is cost effective.
- See following slide
The Bio-Tech Company for the New Millennium
8Physical Disruption Of Bacterial Cells
- From INDA "Presentation on Anti-microbial Agents
Test Methods" at INTC 2002 Meeting, September
26-26, 2002, Atlanta, Georgia, Curtis White,
author.
The Bio-Tech Company for the New Millennium
9Benefits of the NIMBUS Substrate
- Highly effective against pathogenic bacteria.
- Virucidal and fungicidal.
- Quick and prolonged action.
- Rapid absorbency.
- High absorbent capacity.
- Hemostatic action.
- Eliminates bacteria that cause food and body
odors. - Eliminates fungi that cause athletes foot and
mildew. - Launderable.
The Bio-Tech Company for the New Millennium
10Benefits of NIMBUS Large Economic Opportunity
- Multiple applications
- Flexible design
- Patents pending
- Exclusively available
- Low cost
The Bio-Tech Company for the New Millennium
11QMT NIMBUS Test Results
- Broad spectrum microbicidal efficacy
- Bacterial kill rates
- Duration of action
- Twice inoculated effectiveness
- Zone of Inhibition
- Hemostatic efficacy
- Leachability
- Cytotoxicity
- Animal/Clinical safety tests
The Bio-Tech Company for the New Millennium
12Broad spectrum Microbicidal efficacy
- Kill levels for Percent killed
- Staphylococcus aureus gt 99.9999
- Eschericia coli gt 99.9999
- Klebsiella pneumoniae gt 99.9999
- Pseudomonas aeruginosa gt 99.9999
- Proteus vulgaris gt 99.9999
- Serratia marcescens gt 99.9999
- Enterococcus faecalis gt 99.9999
- Enterobacter aerogenes gt 99.9999
- Candida albicans gt 99.9995
- Bacteriophage MS-2 (an RNA virus) gt 99.994
- Bacteriophage PRD1 (a DNA virus) gt 99.87
- Tested in 10 bovine serum with eighteen hours
of exposure
The Bio-Tech Company for the New Millennium
13High kill rate starts in minutes lasts for hours
Percentage killed within indicated time
- Tested in 10 bovine serum
14Microbicidal Effect Is Prolonged
Duration of microbicidal efficacy in the presence
of 10 bovine serum
The Bio-Tech Company for the New Millennium
15Repeated Inoculation Test Results
The results indicate that NIMBUS kills all but
one in a million bacteria per ml. NIMBUS is
more effective in eliminating over a million
cells per ml. than a similar bactericidal
treatment..
- Repeated inoculation Colony forming units (cfu)
on 0.1-gram gauze strips following inoculation
with the indicated bacteria, overnight
incubation, re- inoculation, and overnight
incubation
The Bio-Tech Company for the New Millennium
16Zone of Inhibition -- No Effect of Active Agent
Beyond Substrate
Effect of Gauze Extract on Bacterial
Growth Antimicrobial release test of gauze after
soaking in PBS for 4 hours
The Bio-Tech Company for the New Millennium
17Zone of Inhibition controlGauze Sponges With No
Microbicide
- Samples were inoculated with various volumes of
5.8 x 10E3 cfu/mL of E. coli in PBS
(counter-clockwise from top right 0.5 mL, 0.75
mL, 2.0 mL, and 1.25 mL), and then incubated for
15 hours at 37 degrees C tryptic soy agar (Difco)
containing 0.01 TTC. Red color indicates areas
of bacterial metabolism.
The Bio-Tech Company for the New Millennium
18Zone of Inhibition Gauze Sponges With NIMBUS
- Samples were inoculated with various volumes of
5.8 x 10E3 cfu/mL of E. coli in PBS
(counter-clockwise from top right 0.5 mL, 0.75
mL, 2.0 mL, and 1.25 mL), and then incubated for
15 hours at 37 degrees C tryptic soy agar (Difco)
containing 0.01 TTC. Red color indicates areas
of bacterial metabolism.
The Bio-Tech Company for the New Millennium
19What Does Having No Zone Of Inhibition Mean?
- What this test shows is that the microbicide is
bonded and wont migrate from the substrate.
That means its capacity to continue acting isnt
depleted. It also means it does not have a
microbicide that can escape from the material to
which it has been bonded. - In the photo of the control the red area showing
bacterial growth extends beyond the sponges on
the lower half of the photo because the volumes
(1.25ml. And 2.0 ml.) of inoculum exceed the
capacity of the sponges which have no
microbicide. All the area of the inoculum is
therefore red. - In the photo of the NIMBUS sponges the samples
in the lower two petri dishes show bacterial
growth beyond the edges because the microbicide
doesnt leach from the sponges and kill bacteria
outside their periphery.
20Rat Liver Hemorrhage Model
- The liver of an anesthetized rat is placed on a
Teflon slide. A stab injury is made to the liver
with a scalpel, and a 1 cm disk of the test
dressing is placed on the wound. Bleeding time is
measured in 15 second intervals.
The Bio-Tech Company for the New Millennium
21Rat Liver Hemorrhage Model
- The cellulose sponge on the left is saturated
while the QMT SAP sample on the right rapidly
absorbs about 50x its weight in blood and stops
the hemorrhage.
22QMT SAP Dressing and Hemorrhage Control
The Bio-Tech Company for the New Millennium
23Summary Hemorrhage Experiments
- QMTs super absorbent, microbicidal dressing
promotes clotting and rapidly controls major
hemorrhage in rat liver laceration model. - QMTs super absorbent, microbicidal dressing
performed superiorly or equivalently to other
dressings that are approved for hemorrhage
control in the rat liver laceration model - Avitene
- Surgicel
- Gel foam
- Only QMT's dressing has microbicidal activity.
- QMT's dressing can be constructed to be
biodegradable.
The Bio-Tech Company for the New Millennium
24Cytotoxicity Agent Not Toxic
- Results of Cytotoxicity Test (ASTM F895-84)
Agar Diffusion Method - USP 24 Section 87 Definitions
- Grade 0 None - No detectable zone
- Grade 1 Slight - Some malformed or degenerated
cells - Grade 2 Mild - Zone limited to area under the
specimen - Grade 3 Moderate - Zone extends 0.5 to 1.0 cm.
beyond specimen - Grade 4 Severe - Zone extends 1.0 cm beyond
specimen
25Leachability Agent Is Not Extractable
- Effect of Gauze Eluant on Bacterial Growth
-
-
- Antimicrobial release after 42 hours on a rotary
shaker
The Bio-Tech Company for the New Millennium
26Animal/Clinical Test Results
- Rabbit eye irritation
- Results Non-irritating (1)
- Primary Skin Irritation
- Results Non-irritating (2)
- Guinea Pig Dermal Sensitization
- Results Non-sensitizing(3)
- (1) Protocol CL 1003
- (2) Protocol CL 1005
- (3) Protocol CL 1015
- Note All testing conducted by Geneva Test Labs,
PO Box 140, Elkhorn, W I
The Bio-Tech Company for the New Millennium
27MARKETS APPLICATIONS
- COMMERCIAL
- Preservation
- Fungicide in interior wallboard or exterior
siding
NIMBUS
- CONSUMER
- Wound Care
- Apparel Footwear
- Personal Products
- Household Products
- INSTITUTIONAL
- Hotels/Motels
- Restaurants
- Hospital Products
28Market Applications Consumer
The Bio-Tech Company for the New Millennium
29Opportunities to Enhance Adult Diaper, Feminine
Care and Wipe products
The Bio-Tech Company for the New Millennium
30Fabric/Personal Care NIMBUS Kills Problem
Bacteria
NIMBUS Efficacy (kill rate)
Bacteria or fungus
Problem to correct
99.99 99.99 99.94
Proteus vulgaris Pseudomonas aeruginosa Micrococcu
s luteus
Urine odor
Staphylococcus epidermidis Propionibacterium
acne Corynebacterium diphtheriae Micrococcus
luteus
Perspiration odor
99.99 99.99 99.99 99.94
Food Spoilage
99.99 99.99
Escherichia coli (beef, poultry) Salmonella
typhimurium (fish, poultry, beef, eggs)
Skin/diaper rashes athletes foot
Candida albicans Trichophyton mentagrophytes
99.99 99.48
The Bio-Tech Company for the New Millennium
31Market Applications Institutional
- Wound dressings
- Hospital garments
- Surgical drapes and apparel
- Catheters
- Urinary drainage systems
- Blood collection containers
- Facemasks
The Bio-Tech Company for the New Millennium
32Advanced Wound Dressings Key Medical Features
Of Current Technology
- Hemostatic (can add agents to promote healing)
- Protease inhibitors
- Vitamins
- Collagen
- Saline
- Desired Permeability
- Keep wounds moist
- Permits oxygen passage
- Microbicidal (bacteria, fungi, viruses)
- Silver (Ag)
- Iodine (I)
- Chlorhexidine gluconate
- Quaternaries
- Super absorbent
- Gels
- Hydrocolloids
- Hydrogels
- Alginates
The Bio-Tech Company for the New Millennium
33Drawbacks Of Current Absorbent Bactericidal
Technologies
- Super Absorbent
- Hydrocolloids can develop odors, and their
clinical safety on infected wounds has not been
established. - Alginates are unsatisfactory in dry, necrotic
wounds. - Hydrogels cannot be left in place in contaminated
wounds, and they may adhere to some wounds. - Hemostatic
- No product offers this feature as well as the
other two on this list.
- Bactericidal
- Quaternary and other biocide activity degrades in
the presence of bodily fluids - Ag. treated dressings rely upon migration of the
agent. - CHG must migrate into the wound and is rendered
less effective in the presence of mucous or fatty
acid exudates. It may also cause hypersensitivity
reactions. - Povidone Iodine is less effective against
Pseudomonas species.
The Bio-Tech Company for the New Millennium
34Advanced Surgical Drapes Apparel Medical
Objectives
- Restrict the transmission of bacteria.
- Maintain a sterile field.
- Protect patient and staff from bacterial
contamination. - Prevent the soiling of patient and staff.
- Provide modesty coverage.
The Bio-Tech Company for the New Millennium
35Advanced Surgical Drape Apparel Drawbacks
Of Current Bactericidal Technologies
- Not truly broad spectrum.
- Not highly effective.
- May be susceptible to blinding by body fluids.
- May be leachable, thus possibly cytotoxic.
The Bio-Tech Company for the New Millennium
36Advanced Surgical Drapes Apparel Key
Medical Features Of Current Technologies
- Provide water repellent surfaces.
- May be reinforced in areas vulnerable to
challenge. - Drape reinforcement may be absorbent.
- Bactericidal fenestrated area surface.
- Soft, conformable fabrics.
- Lightweight and comfortable.
The Bio-Tech Company for the New Millennium
37NIMBUS Key Benefits Rapid FDA Approval
- Class II medical device.
- Predicate devices include ACTI-Gard Antimicrobial
Incise Drape. - 510(K) approval process.
The Bio-Tech Company for the New Millennium
38Microbicides in other hospital disposables
- CSR Wrap products
- Face Masks
- Isolation Gowns, scrub clothing
- Linens, towels, wipes
- Dressings, bandages
The Bio-Tech Company for the New Millennium
39Market Applications Industrial
- Wood Preservation
- Pesticides
- Protective Clothing
- Wipes
- Food Handling
- Filters
- Paper
- Packing Materials
- Cork Bacteria (TCA)
The Bio-Tech Company for the New Millennium
40Wood Preservation
- Yellow pine samples 10 days after inoculation
with white rot fungus.
The Bio-Tech Company for the New Millennium
41Pesticide
- Comparison of untreated yellow pine block
(right), and NimbusTM treated yellow pine block
(left), after 10 days exposure to subterranean
termites. - Nimbus sample is unwashed.
- Round spots in center are dimples on bottom of
glass sample jar. - Samples are representative results of five
replicates.
The Bio-Tech Company for the New Millennium
42Contact Information
- David Lerner - President
- Tel 561.750.4202
- Email dlerner_at_quickmedtech.com
- Gerald M. Olderman - VP, Research Development
- Tel 781.271.9893
- Email jolderman_at_quickmedtech.com
- URL www.quickmedtech.com
The Bio-Tech Company for the New Millennium